Kite, the cell therapy unit of Gilead Sciences, is adding more tools to its cell therapy toolbox with the acquisition of Tmunity Therapeutics. It’s the company’s second cell therapy deal this month, following a partnership announced with clinical-stage Arcellx.
The Alliance for Regenerative Medicine and 13 biotech companies released a statement outlining bioethical principles on genome editing, including opposition to modifications that can be passed to future generations.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.